Literature DB >> 15996082

Efficacy of rituximab in refractory polymyositis.

Olivier Lambotte1, Rami Kotb, Gwenola Maigne, François-Xavier Blanc, Cécile Goujard, Jean François Delfraissy.   

Abstract

We describe the effectiveness of rituximab, an anti-B lymphocyte monoclonal antibody, in a case of refractory polymyositis with interstitial pulmonary disease and anti-Jo-1 autoantibody (antisynthetase syndrome). Rituximab was well tolerated, and its efficacy in inflammatory myositis should be evaluated.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15996082

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  26 in total

1.  Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Authors:  Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis
Journal:  Curr Rheumatol Rev       Date:  2010-05

2.  Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors:  Mixalis L Kosmidis; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

3.  Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series.

Authors:  Ritu Valiyil; Livia Casciola-Rosen; Grace Hong; Andrew Mammen; Lisa Christopher-Stine
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-09       Impact factor: 4.794

Review 4.  Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.

Authors:  Siamak Moghadam-Kia; Rohit Aggarwal; Chester V Oddis
Journal:  Expert Rev Clin Immunol       Date:  2015-08-27       Impact factor: 4.473

5.  Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature.

Authors:  Paola Caramaschi; Alessandro Volpe; Antonio Carletto; Lisa M Bambara; Domenico Biasi
Journal:  Clin Rheumatol       Date:  2007-01-17       Impact factor: 2.980

Review 6.  [Current treatments of dermatomyositis and polymyositis].

Authors:  J Richter; C Iking-Konert
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

Review 7.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 8.  Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.

Authors:  Pari Basharat; Lisa Christopher-Stine
Journal:  Curr Rheumatol Rep       Date:  2015-12       Impact factor: 4.592

Review 9.  Treatment in myositis.

Authors:  Chester V Oddis; Rohit Aggarwal
Journal:  Nat Rev Rheumatol       Date:  2018-03-29       Impact factor: 20.543

10.  Rituximab in life threatening antisynthetase syndrome.

Authors:  E Vandenbroucke; J C Grutters; J Altenburg; W G Boersma; E J ter Borg; J M M van den Bosch
Journal:  Rheumatol Int       Date:  2009-02-01       Impact factor: 2.631
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.